IPO - Biomea Fusion, Inc.
Form Type: 424B5
Filing Date: 2025-06-17
Corporate Action: Ipo
Type: New
Accession Number: 000119312525142132
Filing Summary: Biomea Fusion, Inc. is conducting a public offering of common stock, pre-funded warrants, and common stock warrants to fund the development of its clinical candidates, primarily focusing on diabetes and obesity treatments. The offering includes shares of common stock and warrants, with specific details on pricing and numbers to be determined. The lead drug candidate, icovamenib, targets metabolic diseases and is currently in clinical trials. The company aims to leverage its proprietary FUSION System for drug discovery. With significant R&D underway, including a promising next-generation GLP-1 receptor agonist, Biomea seeks to establish itself in the diabetes and obesity sector while also addressing dilution risks for investors as it raises capital and undergoes clinical developments. Proceeds from the offering will support the continued development of icovamenib and other pipeline assets, and the company anticipates an IND application for BMF-650 later in 2025.
Additional details:
Common Stock Offered: shares of common stock
Pre Funded Warrants Offered: pre-funded warrants to purchase shares of common stock
Common Stock Warrants Offered: common stock warrants to purchase shares of common stock
Use Of Proceeds: fund the Phase IIb development of icovamenib in type 2 diabetes and the IND filing and clinical development of BMF-650 in obesity and diabetes, as well as for other general corporate purposes.
Last Reported Sale Price: $2.63
Offering Price: $ per share
Expected Delivery Date: on or about, 2025
Number Of Shares Outstanding Post Offering: shares (if the underwriter exercises its option to purchase additional shares in full)
Underwriter Option Period: 30 days
Comments
No comments yet. Be the first to comment!